As noted in Sect. “Examples for current use of biomarkers”, the strength of the relationship was sufficiently compelling that the American Society for Clinical Oncology has since recommended that patients with NSCLC should have their tumors tested for EGFR mutations to determine the most appropriate first-line therapy (Keedy et al. 2011). This evidence concerns the gene EGFR and non-small cell lung carcinoma.